TransMedics Group (TMDX) : 6-year performance

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. 

• Sector: Healthcare
• Industry: Medical Devices
• Full Time Employees: 728
• Founded in 1998 
• Headquartered in Andover, Massachusetts.
• https://www.transmedics.com

 

 

 

TransMedics is in the business of providing the technology for organ transplants. Its Organ Care System (OCS) allows donor organs to be preserved in a living and functioning state by supplying oxygenated blood while they are being transported.

The OCS system sidesteps the limitations of using ice to transport organs such as the heart, liver or lungs. Organs placed in ice for extended periods of time are at risk of being damaged. According to the company, the OCS method has an added advantage since the system allows doctors to assess the organ's viability – something that is difficult to do when the organ is metabolically inactive in cold storage.

On Monday, shares rose 7%, extending a winning streak to four days after the FDA gave an investigational device exemption for OCS in a new clinical trial for heart transplants. The two-phase trial will test longer perfusion time (passage of blood) for heart transplants using OCS and assess the system's ability to support heart transplants from donors after brain death. The trial is expected to exceed 650 patients and may be the largest clinical trial conducted for heart preservation for transplant purposes.

Beta Bionics (BBNX) began trading on the Nasdaq on Thur 30 Jan 25

Beta Bionics is a diabetes technology company. Its iLet Bionic Pancreas is an automated insulin delivery system that received FDA clearance in 2023 for people with Type 1 diabetes. 

• Sector: Healthcare
• Industry: Medical Devices
• Full Time Employees: 279
• Founded by Edward R. Damiano in 2015 
• Headquartered in Irvine, California
• https://www.betabionics.com

Completed its initial public offering (IPO) on January 30, 2025. 

The IPO raised $234.6 million 

Ticker: BBNX

IPO details

• The IPO was for 13,800,000 shares of common stock at $17 per share 
• The underwriters had the option to purchase an additional 1,800,000 shares 
• Beta Bionics also sold 1,000,000 shares in a private placement to an existing investor at $17 per share 
• BofA Securities, Piper Sandler, and Leerink Partners were the lead bookrunners for the offering 

908 Devices (MASS) : 4-year performance

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets.

• Sector: Healthcare
• Industry: Medical Devices
• Full Time Employees: 230
• Incorporated in 2012 
• Headquartered in Boston, Massachusetts
• Website www.908devices.com

 

 

 

 

CeriBell (CBLL) began trading on the Nasdaq on Fri 11 Oct 24

CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. 

The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015.

• Sector(s): Healthcare
• Industry: Medical Devices
• Full Time Employees: 240
• Incorporated in 2014 
• HQ in Sunnyvale, California.
• https://ceribell.com

Opened at $23.26 after pricing 10,606,060 share IPO at $17/share, at the $16-17 expected range.

Ticker: CBLL

Penumbra (PEN) began trading on the NYSE on 18 Sept 15

Penumbra (PEN) prices IPO above range

Penumbra (PEN) which designs and markets devices for the treatment of strokes and other vascular conditions, priced its initial public offering at $30 a share. 

The company sold 4 million shares, valuing it at about $1 billion. The IPO had been expected to price in a range between $25 a share to $28 a share. The Alameda, Calif., company plans to list on the New York Stock Exchange under the ticker symbol PEN.

• The company last year generated $2.2 million of net income on $125 million in revenue, and already has reported $81 million in revenue for the first half of 2015.

Address

1 Penumbra
ALAMEDA, CA 94502-7610
United States

Website 

http://www.penumbrainc.com

Key stats and ratios

	Q1 (Mar '17)	2016
Net profit margin	-4.24%	5.63%
Operating margin	-2.79%	-0.51%
EBITD margin	-	0.36%
Return on average assets	-3.43%	5.18%
Return on average equity	-3.89%	5.94%
Employees	1,500

ConforMIS (CFMS) began trading on Nasdaq on 1 July 2015

• ConforMIS, which makes customized knee replacement implants, sold nine million shares at a price of $15 each. The stock rose to $19.25 by the end of trading Wednesday, giving the company a market value of about $750 million.
• The company, founded in 2004 in Redwood City, Calif., moved to Massachusetts in 2008. It reported $48 million in sales and a loss of nearly $46 million last year.
• Joint bookrunners for the offering are JPMorgan and Deutsche Bank. Co-managers are Wells Fargo Securities, Canaccord Genuity and Oppenheimer. The underwriters have a 30-day option to purchase an additional 1.35 million shares.

• charts 24 March 2017 (1 year 9 months after IPO)

  

Glaukos (GKOS) began trading on the NYSE on 25 June 2015

Glaukos (NYSE:GKOS) is developing surgical devices for treating glaucoma. It priced 6 million shares at an above-range 18. The stock popped 73% to 31.22 in its debut Thursday. It fell 10% Friday.

• The ophthalmic medical technology firm focuses on treatments for glaucoma, a group of disorders that is characterized by elevated intraocular pressure (IOP). This eventually damages the optic nerve which leads to vision loss and blindness. The specific category that the company operates in is called Micro-Invasive Glaucoma Surgery (MIGS). Its sole product is the iStent, the only FDA-approved MIGS device to date. The hollow micro-scale device is implanted in the eye through a small incision in the cornea. It reduces IOP by allowing the drainage of fluid, called aqueous humor. The company has sold over 70,000 iStents to date.   

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company is engaged in the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring one millimeter long and 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye's anterior chamber through a small corneal incision. Glaukos is also engaged in developing a portfolio of micro-scale injectable therapies, including three pipeline products, namely, the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.

Address

26061 Merit Cir Ste 103
LAGUNA HILLS, CA 92653-7010
United States 

Website

http://www.glaukos.com/

InVitae (NVTA) began trading on the NYSE on 12 Feb 2015

Description

Invitae Corporation is a genetic information company. The Company is engaged in genetic diagnostics for hereditary disorders, including breast, colon and pancreatic cancer. The Company utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for physicians and their patients. The Company offers the following panels: Featured cancer panels, Featured cardiology panels and Featured neurology panels. The Company’s tools and services include genetic counseling services, to explain complex genetic concepts; Family History Tool, which allows digitally recording the patient’s pedigree, assessing their risks, as well as deciding on the appropriate genetic test, and Clinvitae, a database of clinically-observed genetic variants aggregated from public sources.

Address

458 Brannan St
SAN FRANCISCO, CA 94107-1713
United States

Website 

https://www.invitae.com

Key stats and ratios

	Q4 (Dec '14)	2014
Net profit margin	-1749.14%	-2960.85%
Operating margin	-1746.63%	-2952.12%
EBITD margin	-	-2807.79%
Return on average assets	-60.80%	-52.22%
Return on average equity	-	-
Employees	161

Nevro (NVRO) began trading on the NASDAQ on 6 November 2014

Description

Nevro Corp. is a medical device company focused on developing solutions in the neuromodulation space. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. The Company’s High-frequency spinal cord stimulation (SCS) system, the HF10 SCS, is a spinal cord simulation therapy, which provides electric pulses at a rate of approximately 10,000 Hz for spinal cord stimulation in the treatment of chronic back and leg pain. The electrical pulses are conveyed by small electrodes placed in the epidural space and connected to a battery-powered generator implanted under the skin. The Nevro Senza SCS system is available in Europe and Australia. It is undergoing a pivotal clinical trial, which is intended to collect data to support an application for a Nevro Senza implantable spinal cord stimulation system. The Company’s SENZA-RCT study is intended to evaluate the safety and effectiveness of the Senza SCS system.

Address

4040 Campbell Ave Ste 210
MENLO PARK, CA 94025-1053
United States 

Website 

http://www.nevro.com

Key stats and ratios

	Q3 (Sep '14)	2013
Net profit margin	-90.97%	-110.70%
Operating margin	-74.97%	-107.03%
EBITD margin	-	-106.83%
Return on average assets	-53.15%	-41.78%
Return on average equity	-	-
Employees	114

Intersect ENT (XENT) began trading on the NASDAQ on 24 July 2014

• Acquired by Medtronic (MDT)  (Aug 2021)

Description

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company has developed a drug-eluting bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ear, nose and throat (ENT), physicians to improve patient care. The Company’s initial products PROPEL and PROPEL mini, is a drug-eluting implants approved by the United States Food and Drug Administration (FDA), for use in patients with chronic sinusitis. The Company’s two commercial products PROPEL and PROPEL mini, are designed to improve the outcomes of sinus surgery by reducing postoperative inflammation and scarring from the underlying condition, as well as the surgery.

Address

1555 Adams Dr
MENLO PARK, CA 94025-1439
United States 

Website 

http://www.intersectent.com

Key stats and ratios

	Q3 (Sep '14)	2013
Net profit margin	-64.67%	-102.44%
Operating margin	-64.85%	-100.20%
EBITD margin	-	-97.38%
Return on average assets	-60.04%	-129.99%
Return on average equity	-	-
Employees	179

Rewalk Robotics (RWLK) began trading on the NASDAQ on 12 Sept 2014

September 12, 2024,: ReWalk Robotics changed its name  to Lifeward Ltd.  (Nasdaq: LFWD) to reflect its broader mission in the physical limitations and disabilities market.

• Website: golifeward.com

Description

Rewalk Robotics Ltd is an Israel-based medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company has developed and is continuing to commercialize ReWalk, an exoskeleton that uses its patented tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. The Company offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk is a product that can fundamentally change the health and life experiences of users. ReWalk controls movement using subtle changes in the user’s center of gravity.

Address

Kochav Yokneam Building, Floor 6, PO Box 161
YOKNEAM, 2069200
Israel

Website 

http://rewalk.com

Key stats and ratios

	Q2 (Jun '14)	2013
Net profit margin	-938.00%	-766.81%
Operating margin	-763.80%	-550.69%
EBITD margin	-	-544.90%
Return on average assets	-278.55%	-185.16%
Return on average equity	-	-822.10%
Employees	63

Iradimed (IRMD) began trading on the NASDAQ on 16 July 2014

Description

iRadimed Corporation is a provider of non-magnetic intravenous (IV) infusion pump systems that are safe for use during magnetic resonance imaging (MRI) procedures. Electromechanical medical devices and pumps contain magnetic and electronic parts which generate radio frequency (RF) noise, create interference and are dangerous to operate in the presence of the smagnet which drives an MRI. Its mRidium (3850/3860+) IV pump systems have been designed with non-ferrous parts, ceramic ultrasonic motors, non-magnetic mobile stand and other special features in order to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. The Company’s pump solution provides a seamless approach to providing IV fluids before, during and after an MRI scan. As of March 31, 2014, it has approximately 1,917 IV infusion pump systems installed globally.

Address

7457 Aloma Ave, SUITE 201
WINTER PARK, FL 32792-9172
United States

Website 

http://www.iradimed.com

Key stats and ratios

	Q1 (Mar '14)	2013
Net profit margin	14.71%	17.08%
Operating margin	23.17%	24.58%
EBITD margin	-	25.80%
Return on average assets	28.47%	30.89%
Return on average equity	36.40%	44.82%
Employees	46

Signal Genetics (SGNL) began trading on the NASDAQ on 18 June 2014

• As of February 13, 2017, Signal Genetics, Inc. was acquired by miRagen Therapeutics, Inc.,  a privately-held biopharmaceutical company, in a reverse merger transaction. 
• The combined company is named Miragen Therapeutics and trades under the ticker "MGEN."

Description

Signal Genetics, Inc. is a commercial-stage, molecular diagnostic company focused on providing diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. It develops, validates and delivers diagnostic services that enable better patient-care decisions.

Address

14TH FLOOR, 667 MADISON AVE.
NEW YORK, NY 10065
United States

Key stats and ratios

	Q1 (Mar '14)	2013
Net profit margin	-64.70%	-50.03%
Operating margin	-15.28%	-4.55%
EBITD margin	-	-6.90%
Return on average assets	-78.99%	-66.93%
Return on average equity	-	-
Employees	14

Inogen (INGN) began trading on the NASDAQ on 14 February 2014

Description

Inogen, Inc. (Inogen) is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It offers Inogen One systems for the patients who require long-term oxygen therapy. The Company’s products include Inogen One G3 and Inogen One G2. The Inogen One G3 and Inogen One G2, weighs at approximately 4.8 and 7.0 pounds, respectively, are amongst the most lightweight portable oxygen concentrators. It markets its product offerings, the Inogen One G3 and the Inogen One G2, as single solutions for oxygen therapy. One G2 is effective for nocturnal use. Its Inogen One G2 and the Inogen One G3 are sub-5 and sub-10 pound portable oxygen.

Address

326 Bollay Drive
GOLETA, CA 93117
United States 

Website 

http://www.inogen.net

Key stats and ratios

	Q3 (Sep '13)	2012
Net profit margin	3.91%	1.16%
Operating margin	4.48%	1.71%
EBITD margin	-	11.97%
Return on average assets	5.32%	1.57%
Return on average equity	-	-
Employees	77

Amedica (AMDA) began trading on the NASDAQ on 13 February 2014

Amedica Corp. (NASDAQ: AMDA) is a medical device maker that began trading on Thursday. The IPO offered 3.5 million shares at a price of $5.75 a share, a far cry from the expected range of $10 to $12. Underwriters have a 30-day option on an additional 525,000 shares. Shares closed at $5.39 on Thursday and at $5.68 on Friday.

Description

Amedica Corporation (Amedica) is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices. The Company market spinal fusion products and are developing products for use in total hip and knee joint replacements. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States and Europe for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride-based spinal fusion products, it markets a complementary line of non-silicon nitride spinal fusion products which allows us to provide surgeons and hospitals with a broader range of products. These products include three lines of spinal fusion devices and five types of orthobiologics, which are used by surgeons to help promote bone growth and fusion in spinal fusion procedures.

Address

1885 West 2100 South
SALT LAKE CITY, UT 84119
United States 

Website 

http://www.amedicacorp.com

Key stats and ratios

	Q3 (Sep '13)	2012
Net profit margin	-48.69%	-151.89%
Operating margin	-38.73%	-127.26%
EBITD margin	-	-41.44%
Return on average assets	-32.11%	-74.01%
Return on average equity	-	-
Employees	74

Tandem Diabetes Care (TNDM) began trading on the NASDAQ on 14 November 2013

Description

Tandem Diabetes Care, Inc. is a medical device company with an approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company designed and commercialized its flagship product, the t:slim Insulin Delivery System, or t:slim, based on its technology platform and consumer-focused approach. Its technology platform features Micro-Delivery Technology, a miniaturized pumping mechanism, which draws insulin from a flexible bag within the pump’s cartridge rather than relying on a syringe and plunger mechanism. The Company also applies the science of human factors to its design and development process, which seeks to optimize its devices to the intended users, allowing users to successfully operate the devices in their intended environment.

Address

Suite 200, 11045 Roselle Street
SAN DIEGO, CA 92121
United States 

Website 

www.tandemdiabetes.com

Key stats and ratios

	Q3 (Sep '13)	2012
Net profit margin	-167.96%	-1334.11%
Operating margin	-155.96%	-1335.44%
EBITD margin	-	-1252.28%
Return on average assets	-97.19%	-122.74%
Return on average equity	-	-
Employees	307